Introduction: Supracrestal tissue height establishment is a crucial factor influencing peri‐implant marginal bone modifications prior to prosthesis delivery. If mucosal thickness is insufficient, peri‐implant marginal bone resorption occurs to allow appropriate supracrestal tissue height formation. This study evaluates if marginal bone resorption occurring around tissue‐level implants before prosthetic loading could be compensated by adapting apico‐coronal positioning to mucosal thickness.Methods: Patients requiring placement of one single implant in the posterior mandible were treated with tissue‐level implants with a 3‐mm high transmucosal machined component and moderately rough implant body. Based upon vertical mucosal thickness measured after buccal flap reflection, implants were placed with the treated part: (group 1) 2 mm below crestal level in presence of thin mucosa (3.5 mm).Results: Forty‐nine implants, placed in 49 patients were included in final analysis (group 1: 18 implants; group 2: 16 implants; group 3: 15 implants). Mean marginal bone resorption after 5 months of healing was 0.66 ± 0.49 mm, 0.32 ± 0.41 mm, and 0.22 ± 0.52 mm in groups 1, 2, and 3, respectively. Inter‐group analysis highlighted significant differences between the three groups after ANOVA test (p = 0.025). However, adaptation of apico‐coronal implant positioning in relation to mucosal thickness, allowed to avoid early exposure of the treated surface in 100%, 93.7%, and 53.3% of the implants in groups 1, 2, and 3, respectively.Conclusion: During supracrestal tissue height formation, tissue‐level implants inserted adapting apico‐coronal positioning in relation to mucosal thickness exhibited greater marginal bone resorption at sites with thin mucosa than at sites with medium or thick mucosa. However, anticipating supracrestal tissue height establishment by adapting apico‐coronal implant positioning in relation to mucosal thickness may effectively prevent unwanted exposure of treated implant surface.
11 June 2025 in Clinical Implant Dentistry and Related Research
Introduction: Early marginal bone loss (EMBL) is a non‐infective phenomenon occurring around the implant neck from placement to the first year of prosthetic function, being influenced by both surgical and prosthetic factors. This multi‐center prospective study assesses the impact of different variables potentially influencing marginal bone stability during the period from crown delivery to 18 months of functional loading.Methods: Forty‐seven patients requiring a single posterior mandibular implant were selected according to specific criteria. Tissue‐level implants were placed at different crestal bone levels based on vertical mucosal thickness and followed in an unsubmerged healing protocol, as described in a previous study evaluating peri‐implant bone levels (PBL) from implant placement (T0) to crown delivery (T1). The present study continues this evaluation, focusing on MBL from T1 to 18 months post‐loading (T2). Host‐related factors (age, gender, smoking, history of periodontitis, vertical mucosal thickness) and specific prosthetic parameters, including crown mesio‐distal dimension, emergence angle, and transmucosal collar height were recorded. Multiple linear regression analysis explored associations between MBL and prosthetic or patient‐related factors, with significance set at p < 0.05.Results: Marginal bone levels remained stable from T1 to T2, with no significant association between MBL and host‐related factors or defined prosthetic variables. However, total MBL from T0 to T2 was significantly higher around implants with thin mucosa at T0 compared to medium and thick mucosa. Multivariate analysis (T0‐T2) identified thin mucosa and smoking as significant MBL predictors.Conclusion: From T1 to T2, marginal bone levels around tissue‐level implants remain stable, with no significant influence from variables analyzed. Conversely, peri‐implant bone resorption between T0 and T2 is significantly associated with thin mucosa (primarily affecting T0‐T1) and smoking.Trial Registration: www.clinicaltrials.gov: NCT05363306